Tags

Type your tag names separated by a space and hit enter

Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
J Clin Endocrinol Metab. 2009 Jan; 94(1):171-80.JC

Abstract

CONTEXT

Bone strength and fracture resistance are determined by bone mineral density (BMD) and structural, mechanical, and geometric properties of bone. DESIGN, SETTING, AND OBJECTIVES: This randomized, double-blind, placebo-controlled outpatient study evaluated effects of once-monthly oral ibandronate on hip and lumbar spine BMD and calculated strength using quantitative computed tomography (QCT) with finite element analysis (FEA) and dual-energy x-ray absorptiometry (DXA) with hip structural analysis (HSA).

PARTICIPANTS

Participants were women aged 55-80 yr with BMD T-scores -2.0 or less to -5.0 or greater (n = 93).

INTERVENTION

Oral ibandronate 150 mg/month (n = 47) or placebo (n = 46) was administered for 12 months.

OUTCOME MEASURES

The primary end point was total hip QCT BMD change from baseline; secondary end points included other QCT BMD sites, FEA, DXA, areal BMD, and HSA. All analyses were exploratory, with post hoc P values.

RESULTS

Ibandronate increased integral total hip QCT BMD and DXA areal BMD more than placebo at 12 months (treatment differences: 2.2%, P = 0.005; 2.0%, P = 0.003). FEA-derived hip strength to density ratio and femoral, peripheral, and trabecular strength increased with ibandronate vs. placebo (treatment differences: 4.1%, P < 0.001; 5.9%, P < 0.001; 2.5%, P = 0.011; 3.5%, P = 0.003, respectively). Ibandronate improved vertebral, peripheral, and trabecular strength and anteroposterior bending stiffness vs. placebo [7.1% (P < 0.001), 7.8% (P < 0.001), 5.6% (P = 0.023), and 6.3% (P < 0.001), respectively]. HSA-estimated femoral narrow neck cross-sectional area and moment of inertia and outer diameter increased with ibandronate vs. placebo (respectively 3.6%, P = 0.003; 4.0%, P = 0.052; 2.2%, P = 0.049).

CONCLUSIONS

Once-monthly oral Ibandronate for 12 months improved hip and spine BMD measured by QCT and DXA and strength estimated by FEA of QCT scans.

Authors+Show Affiliations

New Mexico Clinical Research & Osteoporosis Center, 300 Oak Street NE, Albuquerque, New Mexico 87106, USA. lewiecki@aol.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18840641

Citation

Lewiecki, E Michael, et al. "Once-monthly Oral Ibandronate Improves Biomechanical Determinants of Bone Strength in Women With Postmenopausal Osteoporosis." The Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 1, 2009, pp. 171-80.
Lewiecki EM, Keaveny TM, Kopperdahl DL, et al. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2009;94(1):171-80.
Lewiecki, E. M., Keaveny, T. M., Kopperdahl, D. L., Genant, H. K., Engelke, K., Fuerst, T., Kivitz, A., Davies, R. Y., & Fitzpatrick, L. A. (2009). Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. The Journal of Clinical Endocrinology and Metabolism, 94(1), 171-80. https://doi.org/10.1210/jc.2008-1807
Lewiecki EM, et al. Once-monthly Oral Ibandronate Improves Biomechanical Determinants of Bone Strength in Women With Postmenopausal Osteoporosis. J Clin Endocrinol Metab. 2009;94(1):171-80. PubMed PMID: 18840641.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. AU - Lewiecki,E Michael, AU - Keaveny,Tony M, AU - Kopperdahl,David L, AU - Genant,Harry K, AU - Engelke,Klaus, AU - Fuerst,Thomas, AU - Kivitz,Alan, AU - Davies,Richard Y, AU - Fitzpatrick,Lorraine A, Y1 - 2008/10/07/ PY - 2008/10/9/pubmed PY - 2009/2/13/medline PY - 2008/10/9/entrez SP - 171 EP - 80 JF - The Journal of clinical endocrinology and metabolism JO - J Clin Endocrinol Metab VL - 94 IS - 1 N2 - CONTEXT: Bone strength and fracture resistance are determined by bone mineral density (BMD) and structural, mechanical, and geometric properties of bone. DESIGN, SETTING, AND OBJECTIVES: This randomized, double-blind, placebo-controlled outpatient study evaluated effects of once-monthly oral ibandronate on hip and lumbar spine BMD and calculated strength using quantitative computed tomography (QCT) with finite element analysis (FEA) and dual-energy x-ray absorptiometry (DXA) with hip structural analysis (HSA). PARTICIPANTS: Participants were women aged 55-80 yr with BMD T-scores -2.0 or less to -5.0 or greater (n = 93). INTERVENTION: Oral ibandronate 150 mg/month (n = 47) or placebo (n = 46) was administered for 12 months. OUTCOME MEASURES: The primary end point was total hip QCT BMD change from baseline; secondary end points included other QCT BMD sites, FEA, DXA, areal BMD, and HSA. All analyses were exploratory, with post hoc P values. RESULTS: Ibandronate increased integral total hip QCT BMD and DXA areal BMD more than placebo at 12 months (treatment differences: 2.2%, P = 0.005; 2.0%, P = 0.003). FEA-derived hip strength to density ratio and femoral, peripheral, and trabecular strength increased with ibandronate vs. placebo (treatment differences: 4.1%, P < 0.001; 5.9%, P < 0.001; 2.5%, P = 0.011; 3.5%, P = 0.003, respectively). Ibandronate improved vertebral, peripheral, and trabecular strength and anteroposterior bending stiffness vs. placebo [7.1% (P < 0.001), 7.8% (P < 0.001), 5.6% (P = 0.023), and 6.3% (P < 0.001), respectively]. HSA-estimated femoral narrow neck cross-sectional area and moment of inertia and outer diameter increased with ibandronate vs. placebo (respectively 3.6%, P = 0.003; 4.0%, P = 0.052; 2.2%, P = 0.049). CONCLUSIONS: Once-monthly oral Ibandronate for 12 months improved hip and spine BMD measured by QCT and DXA and strength estimated by FEA of QCT scans. SN - 0021-972X UR - https://www.unboundmedicine.com/medline/citation/18840641/Once_monthly_oral_ibandronate_improves_biomechanical_determinants_of_bone_strength_in_women_with_postmenopausal_osteoporosis_ L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2008-1807 DB - PRIME DP - Unbound Medicine ER -